Understand what the latest cancer research actually shows — from early laboratory findings to clinical trials, FDA approvals, prevention and detection.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
In the randomized, phase 3 PANOVA-3 trial, adding Tumor Treating Fields (TTFields) -- a wearable device that emits alternating electric fields through skin-worn arrays -- to standard chemotherapy significantly extended…
In the dose-optimization portion of the now-terminated phase 2/3 REFRaME-O1 trial, the antibody-drug conjugate luveltamab tazevibulin produced objective responses in patients with platinum-resistant ovarian cancer expressing folate receptor alpha, at…
Participants age 18 Years and older with Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma who meet the study-specific registry eligibility criteria.
Last reviewed
2026-08-14
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-14
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with advanced, heavily pretreated endometrial cancer (n=27 in this cohort), enrolled in the gynecologic expansion cohort of a first-in-human, phase 1 trial. A separate cohort of the SAME trial (n=24) enrolled patients with platinum-resistant ovarian cancer; both cohorts' results are reported together here since they come from the same combination and the same trial, though this record's cancer_type taxonomy tag reflects the endometrial cohort specifically.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Adults with recurrent, platinum-resistant ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing folate receptor alpha (FRα), who received 1-3 prior lines of therapy, enrolled in the dose-optimization portion of a phase 2/3 trial that has since been terminated before its planned randomized phase 3 portion began (see correction_note). Efficacy figures here are from the 25-patient cohort receiving the dosing regimen originally selected for further study.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
Adult and pediatric patients with high-risk neuroblastoma (a cancer arising from immature nerve cells, most common in young children) who showed at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy, enrolled in the single-arm Study 3b and compared against an external control group drawn from a separate NCI/Children's Oncology Group trial (Study ANBL0032).
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adult and pediatric patients with high-risk neuroblastoma who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy, to reduce the risk of relapse.
US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy (Journal of Clinical Oncology). DOI 10.1200/JCO.24.00546, PMID 38917371.
Adults with locally advanced pancreatic adenocarcinoma, randomized to Tumor Treating Fields (TTFields) plus gemcitabine/nab-paclitaxel chemotherapy or chemotherapy alone, in the randomized, open-label, phase 3 PANOVA-3 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with locally advanced pancreatic cancer, used concomitantly with gemcitabine and nab-paclitaxel.
Decision date
2026-02-11
Access notes
A DEVICE approval, not a drug approval -- disclosed as such, not conflated with a pharmaceutical regulatory action.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study (Journal of Clinical Oncology). DOI 10.1200/JCO-25-00746.
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or other large B-cell lymphoma after two or more prior lines of systemic therapy, enrolled in the dose-expansion cohort of the single-arm, open-label, phase 1/2 EPCORE NHL-1 trial.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
Biomarker requirement
CD20-expressing B-cell lymphoma (target of the bispecific antibody; not a patient-selection biomarker test)
Decision date
2023-05-19
Access notes
Requires a step-up dosing schedule and monitoring for cytokine release syndrome, particularly around the first doses.
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial (Journal of Clinical Oncology). DOI 10.1200/JCO.22.01725, PMID 36548927.
Adults with platinum-resistant, PD-L1-positive (CPS >=1) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received one to two prior lines of systemic therapy, randomized to pembrolizumab plus paclitaxel (+/- bevacizumab) or placebo plus paclitaxel (+/- bevacizumab), in the randomized, double-blind, phase 3 ENGOT-ov65/KEYNOTE-B96 trial conducted at 187 sites in 25 countries.
View approval details
Last reviewed
2026-08-13
Regulatory status by jurisdiction
United States (FDA)
Status
FDA-approved for the exact stated cancer/use
Indication
Adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS >=1), who have received one to two prior lines of systemic therapy.
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study (The Lancet). DOI 10.1016/S0140-6736(26)00602-1, PMID 41974150.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In the gynecologic expansion cohort of the first-in-human, phase 1 MYTHIC trial, the combination of lunresertib (a PKMYT1 inhibitor) and camonsertib (an ATR inhibitor) produced durable objective responses in heavily…
Eflornithine (Iwilfin), an oral drug that blocks an enzyme cancer cells use to make polyamines needed for growth, is the first FDA-approved therapy specifically intended to reduce relapse risk in…
Research does not always move through every step in order — some steps are skipped, repeated, or run in parallel, and a promising early result does not guarantee it will reach later stages. This is a general orientation, not a prediction about any specific discovery.
1Laboratory researchStudies in cells or tissue samples, not yet in a living organism.
2Preclinical (animal) researchStudies in animal models, before any human is involved.
3Early human researchThe first small studies in people, often focused on safety.
4Phase 1 trialA small trial testing safety and dosing in people.
5Phase 2 trialA larger trial testing whether a treatment appears to work and is reasonably safe.
6Phase 3 trialA large trial comparing a treatment against the current standard, often across many sites.
7Regulatory reviewA regulator (such as the FDA) reviews trial results to decide whether to approve a treatment for a specific, stated use.
8Clinical / guideline contextClinical guideline bodies decide whether and how an approved treatment fits into standard care.